Activin and Inhibin

ABD957 is a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, with an IC 50 of 0.21 µM for ABHD17B . ABD957 can block N-Ras signaling and the growth of NRAS-mutant AML cells.Appearance:SolidIC50&amp: Target:IC50: 0.21

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC 50 s of 1.2 and 1.3 nM, respectively. Anti-cancer activityIn VivoAbemaciclib metabolite M2 (LSN2839567) is bound to plasma

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC 50 s of 1.2 and 1.3 nM, respectively. Anti-cancer activityIn VivoAbemaciclib metabolite M2 (LSN2839567) is bound to plasma

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC 50 s of 1.2 and 1.3 nM, respectively. Anti-cancer activityIn VivoAbemaciclib metabolite M2 (LSN2839567) is bound to plasma

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC 50 s of 1.2 and 1.3 nM, respectively. Anti-cancer activityIn VivoAbemaciclib metabolite M2 (LSN2839567) is bound to plasma

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC 50 s of 1.2 and 1.3 nM, respectively. Anti-cancer activityIn VivoAbemaciclib metabolite M2 (LSN2839567) is bound to plasma

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.